Effects of histone H4 hyperacetylation on inhibiting MMP2 and MMP9 in human amniotic epithelial cells and in premature rupture of fetal membranes

Song,Zhihui; Yang,Lili; Hu,Wei; Yi,Jianping; Feng,Fumin; Zhu,Lingyan

doi:10.3892/etm.2021.9946

Effects of histone H4 hyperacetylation on inhibiting MMP2 and MMP9 in human amniotic epithelial cells and in premature rupture of fetal membranes

Authors:
- Zhihui Song
- Lili Yang
- Wei Hu
- Jianping Yi
- Fumin Feng
- Lingyan Zhu
View Affiliations

Affiliations: Department of Obstetrics, Maternal and Child Health Hospital of Tangshan, Tangshan, Hebei 063021, P.R. China, Department of Obstetrics, Maternal and Child Health Hospital of Luannan, Luannan, Hebei 063210, P.R. China, School of Public Health, North China University of Science and Technology, Tangshan, Hebei 063021, P.R. China
Published online on: March 22, 2021 https://doi.org/10.3892/etm.2021.9946
Article Number: 515
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histone modification is closely associated with several diseases. The aim of the current study was to investigate the associations among histone acetylation, matrix metalloproteinases (MMPs) and premature rupture of membranes (PROM) during pregnancy. A total of 180 puerperants were divided into three groups: i) Preterm‑PROM (PPROM), ii) term‑PROM (TPROM) and iii) full‑term labor (FTL). Enzyme‑linked immunosorbent assay (ELISA) kits and western blotting were used to determine the protein concentrations of MMP2, MMP9, histone deacetylase (HDAC)1, HDAC2 and HDAC6, and the protein levels of histone H4 lysine (H4K)5 and H4K8 acetylation, respectively, in three types of fetal membranes. Additionally, human amniotic epithelial cells were used to determine the effects of the HDAC inhibitors droxinostat and chidamide on cell viability, histone acetylation and the levels of MMP2, MMP9, HDAC1, HDAC2 and HDAC6 in vitro, using the Cell Counting Kit‑8 assay, western blotting and ELISA, respectively. Furthermore, the effects of droxinostat and chidamide on the invasion and migration abilities of human amniotic epithelial cells were investigated using transwell assays. In fetal membranes, the activities of MMP2 and MMP9 increased in PPROM, but decreased in TPROM. Further, the expression of HDAC1 was decreased and histone hyperacetylation was increased in both PPROM and TRPOM. In vitro experiments revealed that 5 µM droxinostat and 0.5 µM chidamide selectively decreased the level of HDAC and induced acetylation of H4K5 and H4K8. Additionally, the aforementioned HDAC inhibitors reduced human amniotic epithelial cell viability, invasion and migration, and decreased the expression levels of MMP2 and MMP9. The current study revealed a high expression level of MMP2 and MMP9 in PPROM compared with TPROM and FL tissue, which was in accordance with previously published studies. Furthermore, the in vitro tests performed in the current study revealed the effect of histone H4 hyperacetylation on inhibiting MMP2 and MMP9 levels in vitro was similar to that observed in TPROM. The results obtained in the current study may be used as a theoretical guide for clinical treatment of premature rupture of membranes.

View Figures

View References

1	Eleje GU, Adinma JI, Ghasi S, Ikechebelu JI, Igwegbe AO, Okonkwo JE, Okafor CI, Ezeama CO, Ezebialu IU and Ogbuagu CN: Antibiotic susceptibility pattern of genital tract bacteria in pregnant women with preterm premature rupture of membranes in a resource-limited setting. Int J Gynaecol Obstet. 127:10–14. 2014.PubMed/NCBI View Article : Google Scholar
2	Mercer BM: Preterm premature rupture of the membranes. Obstet Gynecol. 101:178–193. 2003.PubMed/NCBI View Article : Google Scholar
3	Raines DA, Wagner A and Salinas A: Intraamniotic infection and the term neonate. Neonatal Netw. 36:385–387. 2017.PubMed/NCBI View Article : Google Scholar
4	Wu T, Shi J, Bao S, Qu Y and Mu DZ: Effect of premature rupture of membranes on maternal infections and outcome of preterm infants. Zhongguo Dang Dai Er Ke Za Zhi. 19:861–865. 2017.PubMed/NCBI View Article : Google Scholar : (In Chinese).
5	Patriota AF, Guerra GV, de Melo BC, Santos AC, Torres Junior AC and Souza AS: Amniotic fluid volume and maternal outcomes in women with preterm premature rupture of membranes. Rev Bras Ginecol Obstet. 36:146–151. 2014.PubMed/NCBI View Article : Google Scholar : (In Portuguese).
6	Romero R, Espinoza J, Goncalves LF, Gomez R, Medina L, Silva M, Chaiworapongsa T, Yoon BH, Ghezzi F, Lee W, et al: Fetal cardiac dysfunction in preterm premature rupture of membranes. J Matern Fetal Neonatal Med. 16:146–157. 2004.PubMed/NCBI View Article : Google Scholar
7	Thomas W and Speer CP: Chorioamnionitis: Important risk factor or innocent bystander for neonatal outcome? Neonatology. 99:177–187. 2011.PubMed/NCBI View Article : Google Scholar
8	Biggio JR Jr, Ramsey PS, Cliver SP, Lyon MD, Goldenberg RL and Wenstrom KD: Midtrimester amniotic fluid matrix metalloproteinase-8 (MMP-8) levels above the 90th percentile are a marker for subsequent preterm premature rupture of membranes. Am J Obstet Gynecol. 192:109–113. 2005.PubMed/NCBI View Article : Google Scholar
9	Shaarawy M and El-Minawi AM: Prolactin and calcitropic hormones in preterm premature rupture of membranes. Int J Gynaecol Obstet. 84:200–207. 2004.PubMed/NCBI View Article : Google Scholar
10	Osaikhuwuomwan JA, Okpere EE, Okonkwo CA, Ande AB and Idogun ES: Plasma vitamin C levels and risk of preterm prelabour rupture of membranes. Arch Gynecol Obstet. 284:593–597. 2011.PubMed/NCBI View Article : Google Scholar
11	Bou-Resli MN, Al-Zaid NS and Ibrahim ME: Full-term and prematurely ruptured fetal membranes. An ultrastructural study. Cell Tissue Res. 220:263–278. 1981.PubMed/NCBI View Article : Google Scholar
12	Niknejad H, Yazdanpanah G and Kakavand M: Extract of fetal membrane would inhibit thrombosis and hemolysis. Med Hypotheses. 85:197–202. 2015.PubMed/NCBI View Article : Google Scholar
13	Mehats C, Schmitz T, Marcellin L and Breuiller-Fouche M: Biochemistry of fetal membranes rupture. Gynecol Obstet Fertil. 39:365–369. 2011.PubMed/NCBI View Article : Google Scholar : (In French).
14	Rodriguez Faba O, Palou-Redorta J, Fernandez-Gomez JM, Algaba F, Eiró N, Villavicencio H and Vizoso FJ: Matrix metalloproteinases and bladder cancer: What is new? ISRN Urol. 2012(581539)2012.PubMed/NCBI View Article : Google Scholar
15	Choo QY, Ho PC, Tanaka Y and Lin HS: Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology (Oxford). 49:1447–1460. 2010.PubMed/NCBI View Article : Google Scholar
16	Bajracharya D, Shrestha B, Kamath A, Menon A and Radhakrishnan R: Immunohistochemical correlation of matrix metalloproteinase-2 and tissue inhibitors of metalloproteinase-2 in tobacco associated epithelial dysplasia. Dis Markers. 2014(197813)2014.PubMed/NCBI View Article : Google Scholar
17	Fortunato SJ, Menon R and Lombardi SJ: MMP/TIMP imbalance in amniotic fluid during PROM: An indirect support for endogenous pathway to membrane rupture. J Perinat Med. 27:362–368. 1999.PubMed/NCBI View Article : Google Scholar
18	Fortunato SJ, Menon R, Ahmed NU, Bourgeois M and Dildy GA: Amniotic fluid concentrations of collagenase-1 and collagenase-3 are increased in polyhydramnios. J Perinat Med. 32:122–125. 2004.PubMed/NCBI View Article : Google Scholar
19	Park CW, Yoon BH, Park JS and Jun JK: A fetal and an intra-amniotic inflammatory response is more severe in preterm labor than in preterm PROM in the context of funisitis: Unexpected observation in human gestations. PLoS One. 8(e62521)2013.PubMed/NCBI View Article : Google Scholar
20	Dubicke A, Akerud A, Sennstrom M, Hamad RR, Bystrom B, Malmstrom A and Ekman-Ordeberg G: Different secretion patterns of matrix metalloproteinases and IL-8 and effect of corticotropin-releasing hormone in preterm and term cervical fibroblasts. Mol Hum Reprod. 14:641–647. 2008.PubMed/NCBI View Article : Google Scholar
21	Sundar IK, Yao H and Rahman I: Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases. Antioxid Redox Signal. 18:1956–1971. 2013.PubMed/NCBI View Article : Google Scholar
22	Legube G and Trouche D: Regulating histone acetyltransferases and deacetylases. EMBO Rep. 4:944–947. 2003.PubMed/NCBI View Article : Google Scholar
23	Xiong C, Guan Y, Zhou X, Liu L, Zhuang MA, Zhang W, Zhang Y, Masucci MV, Bayliss G, Zhao TC and Zhuang S: Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis. FASEB J. 33:8249–8262. 2019.PubMed/NCBI View Article : Google Scholar
24	Vincent ZL, Mitchell MD and Ponnampalam AP: Regulation of TIMP-1 in human placenta and fetal membranes by lipopolysaccharide and demethylating agent 5-aza-2'-deoxycytidine. Reprod Biol Endocrinol. 13(136)2015.PubMed/NCBI View Article : Google Scholar
25	Vadillo-Ortega F, Gonzalez-Avila G, Furth EE, Lei H, Muschel RJ, Stetler-Stevenson WG and Strauss JF III: 92-kd type IV collagenase (matrix metalloproteinase-9) activity in human amniochorion increases with labor. Am J Pathol. 146:148–156. 1995.PubMed/NCBI
26	Vadillo-Ortega F, Hernandez A, Gonzalez-Avila G, Bermejo L, Iwata K and Strauss JF III: Increased matrix metalloproteinase activity and reduced tissue inhibitor of metalloproteinases-1 levels in amniotic fluids from pregnancies complicated by premature rupture of membranes. Am J Obstet Gynecol. 174:1371–1376. 1996.PubMed/NCBI View Article : Google Scholar
27	Poljak M, Lim R, Barker G and Lappas M: Class I to III histone deacetylases differentially regulate inflammation-induced matrix metalloproteinase 9 expression in primary amnion cells. Reprod Sci. 21:804–813. 2014.PubMed/NCBI View Article : Google Scholar
28	Practice bulletins No. 139. Premature rupture of membranes. Obstet Gynecol. 122:918–930. 2013.PubMed/NCBI View Article : Google Scholar
29	Hua Y, Ding S, Zhang W, Zhou Q, Ye W, Chen M and Zhu X: Expression of AQP3 protein in hAECs is regulated by Camp-PKA-CREB signalling pathway. Front Biosci (Landmark Ed). 20:1047–1055. 2015.PubMed/NCBI View Article : Google Scholar
30	Miki T, Lehmann T, Cai H, Stolz DB and Strom SC: Stem cell characteristics of amniotic epithelial cells. Stem Cells. 23:1549–1559. 2005.PubMed/NCBI View Article : Google Scholar
31	Zhu P, Liu Z, Zhou J and Chen Y: Tanshinol inhibits the growth, migration and invasion of hepatocellular carcinoma cells via regulating the PI3K-AKT signaling pathway. Onco Targets Ther. 12:87–99. 2018.PubMed/NCBI View Article : Google Scholar
32	Witkin SS, Nasioudis D, Leizer J, Minis E, Boester A and Forney LJ: Epigenetics and the vaginal microbiome: Influence of the microbiota on the histone deacetylase level in vaginal epithelial cells from pregnant women. Minerva Ginecol. 71:171–175. 2019.PubMed/NCBI View Article : Google Scholar
33	Saigal S and Doyle LW: An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 371:261–269. 2008.PubMed/NCBI View Article : Google Scholar
34	Polimeni M and Prato M: Host matrix metalloproteinases in cerebral malaria: New kids on the block against blood-brain barrier integrity? Fluids Barriers CNS. 11(1)2014.PubMed/NCBI View Article : Google Scholar
35	Strauss JF III: Extracellular matrix dynamics and fetal membrane rupture. Reprod Sci. 20:140–153. 2013.PubMed/NCBI View Article : Google Scholar
36	Romero R, Chaiworapongsa T, Espinoza J, Gomez R, Yoon BH, Edwin S, Mazor M, Maymon E and Berry S: Fetal plasma MMP-9 concentrations are elevated in preterm premature rupture of the membranes. Am J Obstet Gynecol. 187:1125–1130. 2002.PubMed/NCBI View Article : Google Scholar
37	Yan H, Zhu L, Zhang Z, Li H, Li P, Wang Y and Leng M: HMGB1-RAGE signaling pathway in pPROM. Taiwan J Obstet Gynecol. 57:211–216. 2018.PubMed/NCBI View Article : Google Scholar
38	Mano Y, Shibata K, Sumigama S, Hayakawa H, Ino K, Yamamoto E, Kajiyama H, Nawa A and Kikkawa F: Tocilizumab inhibits interleukin-6-mediated matrix metalloproteinase-2 and -9 secretions from human amnion cells in preterm premature rupture of membranes. Gynecol Obstet Invest. 68:145–153. 2009.PubMed/NCBI View Article : Google Scholar
39	Oner C, Schatz F, Kizilay G, Murk W, Buchwalder LF, Kayisli UA, Arici A and Lockwood CJ: Progestin-inflammatory cytokine interactions affect matrix metalloproteinase-1 and -3 expression in term decidual cells: Implications for treatment of chorioamnionitis-induced preterm delivery. J Clin Endocrinol Metab. 93:252–259. 2008.PubMed/NCBI View Article : Google Scholar
40	Kumar D, Schatz F, Moore RM, Mercer BM, Rangaswamy N, Mansour JM, Lockwood CJ and Moore JJ: The effects of thrombin and cytokines upon the biomechanics and remodeling of isolated amnion membrane, in vitro. Placenta. 32:206–213. 2011.PubMed/NCBI View Article : Google Scholar
41	Kwon JS, Kim YS, Cho AS, Cho HH, Kim JS, Hong MH, Jeong HY, Kang WS, Hwang KK, Bae JW, et al: Regulation of MMP/TIMP by HUVEC transplantation attenuates ventricular remodeling in response to myocardial infarction. Life Sci. 101:15–26. 2014.PubMed/NCBI View Article : Google Scholar
42	Nishihara S, Someya A, Yonemoto H, Ota A, Itoh S, Nagaoka I and Takeda S: Evaluation of the expression and enzyme activity of matrix metalloproteinase-7 in fetal membranes during premature rupture of membranes at term in humans. Reprod Sci. 15:156–165. 2008.PubMed/NCBI View Article : Google Scholar
43	Franz MB, Poterauer M, Elhenicky M, Stary S, Birner P, Vinatzer U, Husslein P, Streubel B and Husslein H: Global and single gene DNA methylation in umbilical cord blood cells after elective caesarean: A pilot study. Eur J Obstet Gynecol Reprod Biol. 179:121–124. 2014.PubMed/NCBI View Article : Google Scholar
44	Wang F, Zhang N, Li B, Liu L, Ding L, Wang Y, Zhu Y, Mo X and Cao Q: Heparin defends against the toxicity of circulating histones in sepsis. Front Biosci (Landmark Ed). 20:1259–1270. 2015.PubMed/NCBI View Article : Google Scholar
45	de Ruijter AJ, van Gennip AH, Caron HN, Kemp S and van Kuilenburg AB: Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J. 370:737–749. 2003.PubMed/NCBI View Article : Google Scholar
46	Gregoretti IV, Lee YM and Goodson HV: Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J Mol Biol. 338:17–31. 2004.PubMed/NCBI View Article : Google Scholar
47	Krusche CA, Vloet AJ, Classen-Linke I, von Rango U, Beier HM and Alfer J: Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Hum Reprod. 22:2956–2966. 2007.PubMed/NCBI View Article : Google Scholar
48	Huang Y, Yang W, Zeng H, Hu C, Zhang Y, Ding N, Fan G, Shao L and Kuang B: Droxinostat sensitizes human colon cancer cells to apoptotic cell death via induction of oxidative stress. Cell Mol Biol Lett. 23(34)2018.PubMed/NCBI View Article : Google Scholar
49	Liu J, Li G, Wang X, Wang L, Zhao R, Wang J, Kong Y, Ding J, Li J and Zhang L: Droxinostat, a histone deacetylase inhibitor, induces apoptosis in hepatocellular carcinoma cell lines via activation of the mitochondrial pathway and downregulation of FLIP. Transl Oncol. 9:70–78. 2016.PubMed/NCBI View Article : Google Scholar
50	Xu Y, Zhang P and Liu Y: Chidamide tablets: HDAC inhibition to treat lymphoma. Drugs Today (Barc ). 53:167–176. 2017.PubMed/NCBI View Article : Google Scholar
51	Gao S, Li X, Zang J, Xu W and Zhang Y: Preclinical and clinical studies of chidamide (CS055/HBI-8000), an orally available subtype-selective HDAC inhibitor for cancer therapy. Anticancer Agents Med Chem. 17:802–812. 2017.PubMed/NCBI View Article : Google Scholar
52	Mann BS, Johnson JR, Cohen MH, Justice R and Pazdur R: FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 12:1247–1252. 2007.PubMed/NCBI View Article : Google Scholar
53	Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, et al: Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 30:631–636. 2012.PubMed/NCBI View Article : Google Scholar
54	Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, Mao X, Suarez Saiz F, Gronda M, Eberhard Y, et al: Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 9:246–256. 2010.PubMed/NCBI View Article : Google Scholar
55	Lu X, Ning Z, Li Z, Cao H and Wang X: Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. Intractable Rare Dis Res. 5:185–191. 2016.PubMed/NCBI View Article : Google Scholar